MONMOUTH JUNCTION, N.J.,
July 6, 2016 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its CytoSorb® blood
purification filter to treat deadly inflammation in critically-ill
and cardiac surgery patients around the world, announced that Dr.
Phillip Chan, Chief Executive
Officer of CytoSorbents, will present at the Cantor Fitzgerald
2nd Annual Healthcare Conference to be held July 12-13, 2016 in New
York City.
Conference Presentation Details:
Where:
Le Parker Meridien New York Hotel, 119 W 56th St,
New York, NY 10019
When: Wednesday, July 13,
2016 at 9:00 AM ET
Live Webcast: http://wsw.com/webcast/cantor4/ctso
Conference Website: Cantor Fitzgerald 2nd Annual
Healthcare Conference
A replay of the presentation webcast will be archived for 90
days in the Investor Relations section of the CytoSorbents website,
www.cytosorbents.com/invest. One-on-one meetings with management
can be arranged through the Cantor Fitzgerald conference portal
ahead of the meeting.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its
flagship product, CytoSorb®, is approved in the European Union with
distribution in 34 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury, and pancreatitis, as well as in cancer immunotherapy.
These are conditions where the risk of death is extremely high, yet
no effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators,
such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure. CytoSorb® has been used safely in more than 12,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. The Company has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued U.S. patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. For more information, please visit the
Company's websites: http://www.cytosorbents.com and
http://www.cytosorb.com or follow us on Facebook and
Twitter
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and
Twitter
Cytosorbents
Contact: Amy Vogel
Investor
Relations
(732) 329-8885 ext.
*825
avogel@cytosorbents.com
|
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-cantor-fitzgerald-2nd-annual-healthcare-conference-300294369.html
SOURCE CytoSorbents Corporation